Dark

CGEN
Compugen Ltd
stock NASDAQ

At Close

Aug 14, 2026 3:59:11 PM EDT

2.40USD-0.207%(-0.01)191,227

0.00Bid 0.00Ask 0.00Spread

Pre-market

Aug 13, 2026 9:08:30 AM EDT

2.48USD+2.905%(+0.07)0

After-hours

Aug 14, 2026 4:18:30 PM EDT

2.36USD-1.871%(-0.04)199

OverviewOptionsHistoricalExchangesShortsNews

Jan 18, 2022

07:09AM EST Compugen Expands COM701 Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use RTTNews

07:05AM EST Compugen Expands Announces New US Patent Covering Triple Combination Use With Anti-PD-1 And Anti-TIGIT Antibodies Benzinga

07:01AM EST Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent PR Newswire

Dec 9, 2021

09:45PM EST Compugen Presents Preliminary Translational Data Demonstrating Immune Activation In The Tumor Microenvironment By COM701 At The TIGIT Therapies Digital Summit Benzinga

07:47AM EST Why Compugen Is Rising In Pre-market? RTTNews

07:14AM EST Compugen Presents Preliminary Data Demonstrating Immune Activation In Tumor Microenvironment By COM701 RTTNews

07:01AM EST Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit PR Newswire

Nov 12, 2021

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Compugen Q3 EPS $(0.07) Beats $(0.12) Estimate Benzinga

07:10AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:09AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:04AM EST Compugen Reports Prelim. Results From Phase 1 Dose Escalation Monotherapy Study Of COM902 Benzinga

07:03AM EST Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study Of COM701 With Opdivo And BMS-986207 RTTNews

07:03AM EST Compugen Q3 Net Loss Narrows To $6.2 Mln From $7.8 Mln Last Year RTTNews

07:01AM EST PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021 PR Newswire

07:01AM EST Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy PR Newswire

07:01AM EST PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021 PR Newswire

07:01AM EST Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of PR Newswire

07:01AM EST Compugen Reports Third Quarter 2021 Results PR Newswire

04:26AM EST Earnings Scheduled For November 12, 2021 Benzinga

Nov 11, 2021

08:03AM EST The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts Benzinga

07:10AM EST Compugen Announces Collaboration Expansion With Bristol Myers Squibb Alongside $20 Mln Equity Investment RTTNews

07:03AM EST Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment Benzinga

07:02AM EST Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment PR Newswire - Nov 11 07:00 EDT Benzinga

07:01AM EST Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside PR Newswire

Nov 8, 2021

07:02AM EST Compugen to Present at Upcoming Investor Conferences PR Newswire

Oct 26, 2021

07:01AM EDT Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021 PR Newswire

Oct 13, 2021

01:38PM EDT Compugen Option Alert: Nov 19 $10 Calls at the Ask: 1950 @ $0.25 vs 486 OI; Earnings 11/4 Before Open [est] Ref=$6.44 Benzinga

Oct 4, 2021

07:06AM EDT Compugen To Receive $6 Mln Milestone Payment From AstraZeneca RTTNews

07:03AM EDT Compugen Receives $6M Milestone Payment From AstraZeneca Triggered By First Patient Dosed With TIGIT Bispecific Derived From COM902 Benzinga

07:01AM EDT Compugen Announces Milestone Payment from AstraZeneca Triggered by First PR Newswire

Oct 1, 2021

08:09AM EDT Compugen To Present Data From Anti-TIGIT COM902 Monotherapy And Triple Combination Dose Escalation Studies RTTNews

08:05AM EDT Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple PR Newswire

Sep 14, 2021

09:04AM EDT Compugen to Present at the Cantor Global Healthcare Conference PR Newswire

Aug 26, 2021

07:01AM EDT Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare PR Newswire

Aug 19, 2021

10:12AM EDT Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial Benzinga

07:09AM EDT Compugen Announces Bispecific Antibody Derived From COM902 To Enter Clinical Development Benzinga

07:01AM EDT Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical PR Newswire

Jul 28, 2021

07:28AM EDT Compugen Q2 Loss/shr $0.11 Vs. Loss/shr $0.08 Last Year RTTNews

07:23AM EDT Compugen Q2 EPS $(0.11) Beats $(0.12) Estimate Benzinga

07:01AM EDT Compugen Reports Second Quarter 2021 Results PR Newswire

04:27AM EDT Earnings Scheduled For July 28, 2021 Benzinga

Jul 19, 2021

07:11AM EDT Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207 Benzinga

07:04AM EDT Compugen Doses First Patient In Phase 1/2 Triple Combination Cohort Expansion Of COM701 With Opdivo And BMS-986207 RTTNews

07:01AM EDT of COM701 with Opdivo(r) and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207 PR Newswire

Jul 16, 2021

10:15AM EDT UPDATE: Roth Capital On Compugen: Firm Cites Strategy To Unburden DNAM-1 Pathway To Activate The Immune System Through Dual Blockade Method; Preclinical Methods Demonstrate Antitumor Activity With A Combo Of anti-TIGIT & anti-PVRIG Antibodies Benzinga

10:14AM EDT Roth Capital Maintains Buy Rating On Compugen Ltd. With $28 Price Target Benzinga

Jul 15, 2021

07:07AM EDT Compugen Doses First Patient In Phase 1 Combination Study Of COM902 And COM701 In Advanced Malignancies RTTNews

07:03AM EDT Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies Benzinga

07:02AM EDT Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 PR Newswire

Jul 14, 2021

07:01AM EDT Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021 PR Newswire

Jun 30, 2021

11:25AM EDT UPDATE: Roth Capital On Compugen Buy Rating: Firm Highlights COM701 anti-PVRIG Antibody Demonstrating Activity In A Number Of Solid Tumors Benzinga

11:25AM EDT Roth Capital Maintains Buy Rating On Compugen, Price Target $28. Benzinga

07:24AM EDT Compugen Doses First Patient In COM701/Opdivo Phase 1b Cohort Expansion Study RTTNews

07:01AM EDT Compugen Doses First Patient in COM701/Opdivo(r) (nivolumab) Phase 1b Cohort PR Newswire

Jun 29, 2021

07:01AM EDT Compugen Presents Research Supporting PVRIG as a Novel and Differentiated PR Newswire

Jun 8, 2021

08:02AM EDT Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor Patients Benzinga

07:24AM EDT Compugen Announces Updated Data From Phase 1 Study Of COM701 At ASCO 2021 Annual Meeting RTTNews

07:02AM EDT Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class PR Newswire

Jun 1, 2021

07:01AM EDT Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by PR Newswire

May 13, 2021

10:30AM EDT Shares of Israeli drug development company Compugen Ltd. (CGEN) are up 10 percent on Thursday's trading as the company reported a first-quarter net loss lesser than analysts' expectations. RTTNews

07:22AM EDT Compugen Q1 Net Loss $9.9 Mln Or $0.12/Shr Vs Loss Of $7.1 Mln Or $0.10/Shr Last Year RTTNews

07:19AM EDT Compugen Q1 EPS $(0.12) Beats $(0.13) Estimate Benzinga

07:01AM EDT Compugen Reports First Quarter 2021 Results PR Newswire

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 11, 2021

07:04AM EDT Compugen To Participate At SITC's Targets For Cancer Immunotherapy: A Deep Dive Seminar Series Benzinga

07:02AM EDT Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive PR Newswire

May 10, 2021

07:19AM EDT Compugen Announces Expansion Of Research Collaboration With Johns Hopkins University For A Novel Myeloid Target Discovered by Compugen Benzinga

07:01AM EDT Compugen Announces Expansion of Research Collaboration with Johns Hopkins PR Newswire

May 3, 2021

07:01AM EDT Compugen to Release First Quarter 2021 Results on Thursday, May 13, 2021 PR Newswire

Apr 29, 2021

07:02AM EDT Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the PR Newswire

Apr 27, 2021

07:52AM EDT Compugen's Preclinical Data Shows Therapeutic Potential Of COM902 In Cancer Immunology, Immunotherapy RTTNews

07:08AM EDT Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy Benzinga

07:01AM EDT Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of PR Newswire

Apr 6, 2021

07:42AM EDT SVB Leerink Maintains Outperform on Compugen, Lowers Price Target to $16 Benzinga

Mar 30, 2021

06:29PM EDT Ark Funds Changes Weighting Caps: Could This Mean A Higher Tesla Allocation? Benzinga

Mar 9, 2021

09:16AM EST Compugen Highlights Publication Of Review On Biology And Potential Therapeutic Relevance Of DNAM-1 Axis In Cancer Immunotherapy Benzinga

07:01AM EST Compugen Publishes Review on Biology and Potential Therapeutic Relevance of PR Newswire

Mar 8, 2021

07:01AM EST Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire

Feb 25, 2021

08:21AM EST Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies Benzinga

07:27AM EST Compugen Q4 EPS $(0.10), Inline, Sales $2.00M Benzinga

07:05AM EST Compugen Reports Fourth Quarter and Full Year 2020 Results PR Newswire

07:04AM EST Compugen Announces Data Update from COM701 Phase 1 Clinical Trial PR Newswire

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 22, 2021

01:58PM EST Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings Benzinga

07:08AM EST Compugen Announces Expansion Of Collaboration Agreement With Bristol Myers Squibb; Bristol Myers Squibb To Supply Opdivo For Compugen's Anti-PVRIG Antibody Benzinga

07:01AM EST Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb PR Newswire

Feb 16, 2021

07:01AM EST Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, PR Newswire

Dec 23, 2020

07:03AM EST Compugen Announces First Milestone In License Deal With AstraZeneca On Bispecific, Multi-specific Antibody Products RTTNews

07:03AM EST Compugen Reports Exclusive License To AstraZeneca For Development Of Products Based On Co.'s Pipeline; Co. Entitled To Receive $2M From AstraZeneca Benzinga

07:00AM EST AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products PR Newswire

Nov 10, 2020

07:01AM EST Compugen to Present at Upcoming Investor Conferences PR Newswire

Nov 5, 2020

07:11AM EST Compugen Q3 EPS $(0.09), Inline Benzinga

07:08AM EST Compugen Q3 Net Loss $7.8 Mln Or $0.09/shr Vs. Net Loss $6.5 Mln Or $0.10/shr Last Year RTTNews

07:02AM EST Compugen Reports Third Quarter 2020 Results PR Newswire

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

07:02AM EST Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with PR Newswire

Oct 27, 2020

07:16AM EDT Compugen To Present Research Data On PVRIG At 2020 TIGIT Therapies Digital Summit Today At 11:00 a.m. ET Benzinga

07:01AM EDT Compugen Presents New Research Data Further Supporting PVRIG as a Potentially PR Newswire

Oct 22, 2020

07:01AM EDT Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020 PR Newswire

Sep 30, 2020

07:19AM EDT Compugen Announces Addition Of Nils Lonberg To Scientific Advisory Board RTTNews

07:15AM EDT Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its PR Newswire

Sep 8, 2020

07:14AM EDT Compugen Doses First Patient In Phase 1/2 Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo And Anti-TIGIT Antibody Benzinga

07:08AM EDT Compugen Doses First Patient In Phase 1/2 Triple Combination Study Of COM701 With Opdivo And Anti-TIGIT Antibody RTTNews

07:01AM EDT Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 PR Newswire

Sep 3, 2020

07:01AM EDT Compugen to Present at Upcoming September 2020 Investor Conferences PR Newswire

Aug 28, 2020

07:01AM EDT Compugen Announces Patent For COM902 Benzinga

Aug 19, 2020

06:34AM EDT SVB Leerink Maintains Outperform on Compugen, Raises Price Target to $19 Benzinga

Jul 30, 2020

10:11AM EDT Compugen EArlier Reported Q2 EPS $(0.08) Beats $(0.10) Estimate Benzinga

07:27AM EDT Compugen Q2 Net Loss $6.2 Mln Or $0.08/shr Vs Net Loss $6.0 Mln Or $0.10/shr Last Year RTTNews

07:01AM EDT Compugen Reports Second Quarter 2020 Results PR Newswire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 16, 2020

07:01AM EDT Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020 PR Newswire

document.getElementById("lfzGFL").onerror = function(){this.style.display='none';}; .dark-mode .j5t18y{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .j5t18y{ color: #333333; background-color: white; border: 2px solid #333333; }CGENCompugen Ltdstock NASDAQ

CGEN
Compugen Ltd
stock NASDAQ